Compare INBK & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INBK | SLGL |
|---|---|---|
| Founded | 1999 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.0M | 254.1M |
| IPO Year | 2013 | 2016 |
| Metric | INBK | SLGL |
|---|---|---|
| Price | $28.41 | $76.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $23.25 | ★ $110.00 |
| AVG Volume (30 Days) | 39.0K | ★ 42.4K |
| Earning Date | 04-30-2026 | 05-22-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $11,541,000.00 | N/A |
| Revenue This Year | $279.34 | N/A |
| Revenue Next Year | $12.97 | $223.84 |
| P/E Ratio | $53.09 | ★ N/A |
| Revenue Growth | ★ 101.84 | N/A |
| 52 Week Low | $17.05 | $20.10 |
| 52 Week High | $31.09 | $97.97 |
| Indicator | INBK | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 55.16 | 45.94 |
| Support Level | $25.23 | $67.89 |
| Resistance Level | $29.98 | $81.18 |
| Average True Range (ATR) | 0.80 | 6.36 |
| MACD | -0.11 | -0.89 |
| Stochastic Oscillator | 44.33 | 33.93 |
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.